Table 3. Treatments and support.
| Global | AKI | No AKI |
p
|
|
|---|---|---|---|---|
| (n = 1642) | (n = 618, 40.1%) | (n = 923, 59.9%) | ||
| COVID-19 treatment | ||||
| Hydroxychloroquine/ Chloroquine. n (%) | 1443 (90.8) | 553(89.8) | 840 (91.2) | 0.345 |
| Lopinavir/Ritonavir. n (%) | 949 (60.8) | 358 (60.1) | 552 (60.4) | 0.899 |
| Remdesivir. n (%) | 29 (2.0) | 11 (2.0) | 18 (2.1) | 0.925 |
| Interferon b. n (%) | 352 (23.5) | 169 (29.5) | 168 (19.1) | <0.001 |
| Tocilizumab. n (%) | 527 (35.4) | 182 (32.6) | 327 (37.2) | 0.073 |
| Corticosteroids | 756 (49.2) | 310 (52.6) | 425 (47.4) | 0.048 |
| for shock n (%) | 53 (3.2) | 44 (7.1) | 9 (1.0) | <0.001 |
| for ARDS n (%) | 645 (39.3) | 248 (40.1) | 378 (41.0) | 0.747 |
| for asthma/bronchial hyperreactivity n (%) | 67 (4.1 | 27 (4.4) | 39 (4.2) | 0.891 |
| Hemodynamic support | ||||
| Noradrenaline n (%) | 1112 (67.7) | 518 (83.8) | 560 (60.7) | <0.001 |
| Dobutamine n (%) | 27 (1.6) | 20 (3.2) | 6 (0.7) | <0.001 |
| Dopamine n (%) | 7 (0.4) | 4 (0.6) | 3 (0.3) | 0.448 |
| Adrenaline n (%) | 11 (0.7) | 8 (1.3) | 3 (0.3) | 0.033 |
| Levosimendan n (%) | 2 (0.1) | 1 (0.2) | 1 (0.1) | 1.000 |
| Respiratory Support | ||||
| Oxygen n (%) | 924 (56.33) | 349 (56.5) | 547 (59.3) | 0.276 |
| High-flow nasal cannula n (%) | 651 (39.6) | 214 (34.6) | 412 (59.3) | <0.001 |
| Non-invasive ventilation n (%) | 307 (18.7) | 125 (20.2) | 172 (18.6) | 0.438 |
| Mechanical ventilation n (%) | 1326 (80.8) | 568 (91.9) | 717 (77.7) | <0.001 |
| Prone position n (%) | 1058 (64.4) | 462 (74.8) | 563 (61) | <0.001 |
| ECCO2R n (%) | 7 (0.4) | 5 (0.8) | 2 (0.2) | 0.124 |
| ECMO n (%) | 42 (2.9) | 19 (3.1) | 23 (2.5) | 0.491 |
ARDS- Acute respiratory distress syndrome
ICU- Intensive care unit
ECCO2R- extracorporeal membrane carbon dioxide removal
ECMO- Extracorporeal membrane oxygenation
AKI- Acute kidney injury.